The legislative effort is an attempt to fight the nearly 300 percent increase in the cost of the life saving drug, according to the report.
“I believe there should be transparency across the health care system,” Sen. Yvanna Cancela, D-Nev., who sponsored the bill, told Kaiser Health News.
Nevada would be the first state to track insulin manufacturer profits, as bills addressing the escalating drug costs in other states have stalled.
